Identification of a new methylation site in the Sept9 promoter region for the diagnosis of hepatocellular carcinoma

Background. Over 600,000 people die from hepatocellular carcinoma (HCC) each year worldwide. The disease is often detected at advanced stages and in many cases is not curable. Early diagnostic and monitoring of HCC recurrences remains a substantial problem in clinical oncology. That determines the need for a search for highly sensitive and specific biomarkers for the non-invasive of HCC diagnostics.

The objective of the study. Identification of the hypermethylated locus in the promoter region of the septin 9 (Sept9) gene based on the annotated methylomes from the public databases. Experimental validation of methylation on a pilot panel of paired clinical samples of patients with HCC, as well as tissue samples from patients with benign liver tumors and lymphocytes from healthy donors.

Materials and methods. To analyze the methyl data, samples of HCC from TCGA, hepatocellular adenoma from GEO (Gene Expression Omnibus) depository, peripheral blood cells and tissues of healthy donors from Methbank were used. Experimental validation of methylation levels of the identified site was carried out on a pilot panel of clinical samples by bisulphite pyrosequencing using PyroMark Q24.

Results. Based on the analysis of methylome data, we selected cg20275528 site, which is characterized by high level of methylation in HCC tissues and minimal levels of methylation in non-tumor liver tissue, hepatocellular adenoma and peripheral blood of healthy donors. Experimental testing on a pilot panel of clinical specimens showed that the level of marker site methylation in HCC (42 % median) is significantly higher than in non-tumor liver tissues (3 % median) and benign neoplasms (1.5 % median) and exceeds the threshold value in HCC compared to paired samples of adjacent non-tumor liver tissue in 20 out of 30 studied cases (66.6 %). The general possibility for cg20275528 methylation detection in circulating DNA of plasma in HCC patients was shown.

Conclusion. The obtained results indicate that the approach to the detection and experimental verification of diagnostically significant markers developed and tested in this study can be used to identify new differentially methylated sites and to establish new approaches for non-invasive HCC diagnosis.

1. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortal ity worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018. DOI: 10.3322/caac.21492.

2. Llovet J.M., Zucman-Rossi J., Pikarsky E. et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018. DOI: 10.1038/nrdp.2016.18.

3. Kulik L., El-Serag H.B. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019;156(2):477–91.e1. DOI: 10.1053/j.gastro.2018.08.065.

4. Abelev G.I., Eraiser T.L. Cellular aspects of alpha-fetoprotein reexpression in tumors. Semin Cancer Biol 1999;9(2):95–107.

5. Rich N., Singal A.G. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol 2014;28(5):843–53. DOI: 10.1016/j.bpg.2014.07.018.

6. Gai W., Sun K. Epigenetic Biomarkers in Cell-Free DNA and Applications in Liq uid Biopsy. Genes (Basel) 2019;10(1). DOI: 10.3390/genes10010032.

7. Kustova I.F., Makarova A.S., Lazarevich N.L. Potential of the use of meth ylation biomarkers for diagnostics and prognosis of hepatocellular carcinoma in liquid biopsy. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2018;5(4):8–19. (In Russ.). DOI: 10.17650/2313-805X-2018.

8. De Vos T., Tetzner R., Model F. et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009;55(7):1337–46. DOI: 10.1373/clinchem.2008.115808.

9. Wasserkort R., Kalmar A., Valcz G. et al. Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island. BMC Cancer 2013;13:398. DOI: 10.1186/1471-2407-13-398.

10. Epigenomics, 2016. Epi proColon®. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf. Accessed date: 1 October 2019.

11. Shen N., Wang T., Li D. et al. Hyper methylation of the Sept9 gene suggests significantly poor prognosis in cancer patients: a systematic review and metaanalysis. Front Genet 2019;10:887. DOI: 10.3389/fgene.2019.00887.

12. Villanueva A., Portela A., Sayols S. et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology 2015;61(6):1945–56. DOI: 10.1002/hep.27732.

13. Oussalah A., Rischer S., Bensenane M. et al. Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma. EBioMedicine 2018;30:138–47. DOI: 10.1016/j.ebiom.2018.03.029.

14. Li J., Zhou X., Liu X. Detection of colorectal cancer in circulating cell-free DNA by methylated CpG tandem amplification and sequencing. Clin Chem 2019;65(7):916–26. DOI: 10.1373/clinchem.2019.301804.

15. Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 2017;169(7):1327–41.e23. DOI: 10.1016/j.cell.2017.05.046.

16. Li L.C., Dahiya R. MethPrimer: designing primers for methylation PCRs. Bio informatics 2002;18(11):1427–31. DOI: 10.1093/bioinformatics/18.11.1427.

17. Illumina, 2011. Available at: https://support.illumina.com/array/array_kits/infinium_humanmethylation450_beadchip_kit/downloads.html. Accessed date: 1 October 2019.

18. Xiong Y., Wei Y., Gu Y. et al. DiseaseMeth version 2.0: a major expansion and update of the human disease methylation database. Nucleic Acids Res 2017;45(D1):D888–95. DOI: 10.1093/nar/gkw1123.

19. Li R., Liang F., Li M. et al. MethBank 3.0: a database of DNA methylomes across a variety of species. Nucleic Acids Res 2018;46(D1):D288–95. DOI: 10.1093/nar/gkx1139.

20. Состояние онкологической помощи населению России в 2017 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 236 с.

21. Wittwer C.T., Herrmann M.G., Moss A.A., Rasmussen R.P. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 1997;22(1):130–1. DOI: 10.2144/97221bi01.

22. Malentacchi F., Forni G., Vinci S., Orlando C. Quantitative evaluation of DNA methylation by optimization of a differentialhigh resolution melt analysis protocol. Nucleic Acids Res 2009;37(12):e86. DOI: 10.1093/nar/gkp383.

23. Bergheim J., Semaan A., Gevensleben H. et al. Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study. Br J Cancer 2018;118(9):1217–28. DOI: 10.1038/s41416-018-0035-8.

24. Song L., Yu H., Jia J., Li Y. A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis. Cancer Biomark 2017;18(4):425–32. DOI: 10.3233/CBM-160321.